secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001437749-25-032870
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex announces European Patent Office intent to grant patent for Reqorsa with PD-1 antibodies
--------------------------------------------------------------------------------

- European Patent Office communicated intent to grant patent for Reqorsa gene therapy combined with PD-1 antibodies for cancer.
- Existing patents already granted in US, Japan, Mexico, Russia, Australia, Chile, China, and Singapore.
- Reqorsa initially developed for lung cancer with approved drugs; shown complementary in preclinical studies.
- Company believes Reqorsa's unique attributes may improve current therapies for lung and other cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925032870/0001437749-25-032870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925032870/gnpx20251024_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer